UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 22 von 1109
Datensatz exportieren als...
BibTeX
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Cancer, 2016-03, Vol.122 (5), p.766-772
Steuer, Conor E.
Behera, Madhusmita
Berry, Lynne
Kim, Sungjin
Rossi, Michael
Sica, Gabriel
Owonikoko, Taofeek K.
Johnson, Bruce E.
Kris, Mark G.
Bunn, Paul A.
Khuri, Fadlo R.
Garon, Edward B.
Ramalingam, Suresh S.
2016
Details
Autor(en) / Beteiligte
Steuer, Conor E.
Behera, Madhusmita
Berry, Lynne
Kim, Sungjin
Rossi, Michael
Sica, Gabriel
Owonikoko, Taofeek K.
Johnson, Bruce E.
Kris, Mark G.
Bunn, Paul A.
Khuri, Fadlo R.
Garon, Edward B.
Ramalingam, Suresh S.
Titel
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Ist Teil von
Cancer, 2016-03, Vol.122 (5), p.766-772
Ort / Verlag
United States
Erscheinungsjahr
2016
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities has been understudied. The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population. METHODS Patients with metastatic lung adenocarcinomas from 14 US sites were enrolled in the LCMC1. Tumor samples were collected from 2009 through 2012 with multiplex genotyping performed on 10 oncogenic drivers (KRAS, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase (ALK) rearrangements, ERBB2 [formerly human epidermal growth factor receptor 2], BRAF, PIK3CA, MET amplification, NRAS, MEK1, and AKT1). Patients were classified as white, Asian, African American (AA), or Latino. The driver mutation frequency, the treatments, and the survival from diagnosis were determined. RESULTS One thousand seven patients were included. Whites represented the majority (n = 838); there were 60 AAs, 48 Asians, and 28 Latinos. Asian patients had the highest rate of oncogenic drivers with 81% (n = 39), and they were followed by Latinos with 68% (n = 19), whites with 61% (n = 511), and AAs with 53% (n = 32). For AAs, the EGFR mutation frequency was 22%, the KRAS frequency was 17%, and the ALK frequency was 4%. Asian patients were most likely to receive targeted therapies (51% vs 27% for AAs). There were no significant differences in overall survival. CONCLUSIONS Differences were observed in the prevalence of oncogenic drivers in lung adenocarcinomas and in subsequent treatments among racial groups. The lowest frequency of drivers was seen for AA patients; however, more than half of AA patients had a driver, and those treated with targeted therapy had outcomes similar to those of other races. Cancer 2016;122:766–772. © 2015 American Cancer Society. The discovery of oncogenic drivers has ushered in a new era for lung cancer and other cancers, but the prevalence and impact of these mutations in lung adenocarcinomas in different racial/ethnic minorities are understudied. The Lung Cancer Mutation Consortium 1 database has been investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.29812
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5038591
Format
–
Schlagworte
Adenocarcinoma - ethnology
,
Adenocarcinoma - genetics
,
Adenocarcinoma - pathology
,
Adenocarcinoma of Lung
,
Adolescent
,
Adult
,
African Americans - genetics
,
Aged
,
Aged, 80 and over
,
Anaplastic Lymphoma Kinase
,
Asian Americans - genetics
,
Brain Neoplasms - ethnology
,
Brain Neoplasms - genetics
,
Brain Neoplasms - secondary
,
Class I Phosphatidylinositol 3-Kinases
,
disparities
,
ErbB Receptors - genetics
,
Ethnic Groups - genetics
,
European Continental Ancestry Group - genetics
,
Female
,
genomics
,
GTP Phosphohydrolases - genetics
,
Hispanic Americans - genetics
,
Humans
,
Liver Neoplasms - ethnology
,
Liver Neoplasms - genetics
,
Liver Neoplasms - secondary
,
lung cancer
,
Lung Neoplasms - ethnology
,
Lung Neoplasms - genetics
,
Lung Neoplasms - pathology
,
Male
,
MAP Kinase Kinase 1 - genetics
,
Membrane Proteins - genetics
,
Middle Aged
,
Phosphatidylinositol 3-Kinases - genetics
,
Proto-Oncogene Proteins B-raf - genetics
,
Proto-Oncogene Proteins c-akt - genetics
,
Proto-Oncogene Proteins c-met - genetics
,
Proto-Oncogene Proteins p21(ras) - genetics
,
race
,
Receptor Protein-Tyrosine Kinases - genetics
,
Receptor, ErbB-2 - genetics
,
targeted therapy
,
United States
,
Young Adult
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX